a study on Heart Failure
The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).
Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure
Heart Failure BAROSTIM NEO® Baroreceptor Baroreflex Baroreflex Activation Therapy™ New York Heart Associate Class III Heart Failure
Open to people ages 21 years and up
The artery planned for the BAROSTIM implant must have:
Any of the following within 3 months of randomization:
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02627196.
© 2017 The Regents of the University of California